Related Experiment Videos
From A to Z on CpG
1Coley Pharmaceutical Group, Wellesley, MA 02481, USA. akrieg@coleypharma.com
Trends in Immunology
|April 4, 2002
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity.
Journal for immunotherapy of cancer·2025
Same author
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
Cancer·2025
Same author
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Cancer cell·2024
Same author
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.
Frontiers in oncology·2023
Same author
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
JTO clinical and research reports·2023
Same author
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
Nucleic acid therapeutics·2022
Same journal
Mitochondrial Ca<sup>2+</sup> signaling: A metabolic rheostat defining tumor and immune cell fate.
Trends in immunology·2026
Same journal
Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.
Trends in immunology·2026
Same journal
Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease.
Trends in immunology·2026
Same journal
Metabolic regulatory nodes of the inflammasome and inflammatory cell death.
Trends in immunology·2026